Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Oral semaglutide causes nausea and diarrhoea in about one in ten patients. This usually resolves over time, and dietary changes can help. Severe gastrointestinal side effects may rarely cause dehydration. 

Co-administration with insulin and/or sulphonylurea therapy may increase the risk of hypoglycaemia. If your patient reports symptomatic hypoglycaemia, please consider a reduction in sulphonylurea or insulin dose. You can contact the ASCEND PLUS team for advice.

  • ASCEND PLUS (A Study of Cardiovascular Events iN Diabetes PLUS) is a randomised double-blind placebo-controlled trial sponsored by the University of Oxford.
  • ASCEND PLUS is registered with clinicaltrials.gov (NCT05441267) and ISRCTN (ISRCTN76193287).
  • The UTN universal trial number for ASCEND PLUS is U1111-1284-0262.
  • Protocol [PDF]